ADMA Biologics Inc (ADMA) Expected to Post Quarterly Sales of $6.68 Million
Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce $6.68 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for ADMA Biologics’ earnings, with estimates ranging from $5.50 million to $7.85 million. ADMA Biologics reported sales of $3.33 million during the same quarter last year, which indicates a positive year over year growth rate of 100.6%. The firm is scheduled to announce its next quarterly earnings results on Friday, February 23rd.
On average, analysts expect that ADMA Biologics will report full-year sales of $6.68 million for the current fiscal year, with estimates ranging from $16.30 million to $18.61 million. For the next financial year, analysts forecast that the business will report sales of $38.15 million per share, with estimates ranging from $28.31 million to $48.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that that provide coverage for ADMA Biologics.
Several brokerages have issued reports on ADMA. ValuEngine cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday, November 14th.
A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC grew its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 32.78% of the company’s stock.
ADMA Biologics (ADMA) opened at $2.77 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $5.80.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.